Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Dana Farber Cancer Inst
Boston, Massachusetts
The records below are financial disclosure and conflict of interest records obtained by ProPublica from the National Institutes of Health and dozens of large public universities across the country. The NIH only has records for researchers who seek or receive its funding.
Total Disclosures: 136
| Name | Type | Company | Disclosed Value | Year Filed |
|---|---|---|---|---|
| J Joung | Conflict of Interest | Editas Medicine | $20,000 - $39,999 | 2014 |
| Anthony Letai | Conflict of Interest | Vivid Biosciences | $20,000 - $39,999 | 2018 |
| Anthony Letai | Conflict of Interest | Vivid Biosciences | $20,000 - $39,999 | 2018 |
| Scott Armstrong | Conflict of Interest | C4 Therapeutics | $20,000 - $39,999 | 2018 |
| Eric Fischer | Conflict of Interest | C4 Therapeutics | $20,000 - $39,999 | 2018 |
| Umar Mahmood | Conflict of Interest | CytoSite BioPharma, Inc. | $20,000 - $39,999 | 2017 |
| David Scadden | Conflict of Interest | Agios Pharmaceuticals | $10,000 - $19,999 | 2019 |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | $10,000 - $19,999 | 2019 |
| Ralph Mazitschek | Conflict of Interest | Regenacy Pharmaceuticals | $10,000 - $19,999 | 2017 |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | $10,000 - $19,999 | 2019 |
| William Kaelin | Conflict of Interest | Peloton Therapeutics, Inc. | $10,000 - $19,999 | 2017 |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | $10,000 - $19,999 | 2019 |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | $10,000 - $19,999 | 2019 |
| Scott Armstrong | Conflict of Interest | Epizyme, Inc. | $5,000 - $9,999 | 2018 |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | $0 - $4,999 | 2019 |
| James Bradner | Conflict of Interest | Tensha Therapeutics | $0 - $4,999 | 2013 |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | $0 - $4,999 | 2019 |
| Donald Kufe | Conflict of Interest | Genus Oncology | $0 - $4,999 | 2018 |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | $0 - $4,999 | 2019 |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | $0 - $4,999 | 2019 |
| Cigall Kadoch | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 | 2019 |
| Scott Armstrong | Conflict of Interest | Epizyme, Inc. | $0 - $4,999 | 2018 |
| Cigall Kadoch | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 | 2019 |
| Jae Keith Joung | Conflict of Interest | Beacon Genomics | 2017 | |
| Donald Kufe | Conflict of Interest | Genus Oncology | 2013 | |
| Jae Keith Joung | Conflict of Interest | Poseida Therapeutics | 2017 | |
| Jae Keith Joung | Conflict of Interest | Transposagen Biopharmaceuticals | 2017 | |
| Ralph Mazitschek | Conflict of Interest | Regenacy Pharmaceuticals | 2017 | |
| Donald Kufe | Conflict of Interest | Genus Oncology | 2017 | |
| Donald Kufe | Conflict of Interest | Genus Oncology | 2013 | |
| Loren Walensky | Conflict of Interest | Aileron Therapeutics | 2017 | |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | 2019 | |
| Ralph Mazitschek | Conflict of Interest | Acetylon Pharmaceuticals | 2015 | |
| Anthony Letai | Conflict of Interest | Vivid Biosciences | 2018 | |
| Anthony Letai | Conflict of Interest | Vivid Biosciences | 2018 | |
| Xiaole Shirley Liu | Conflict of Interest | GV20 Oncotherapy | 2019 | |
| Jae Keith Joung | Conflict of Interest | Beacon Genomics | 2017 | |
| Kevin Hughes | Conflict of Interest | Hughes Risk Apps | 2015 | |
| Jae Keith Joung | Conflict of Interest | Pairwise Plants | 2017 | |
| Jae Keith Joung | Conflict of Interest | Pairwise Plants | 2017 | |
| Eric Fischer | Conflict of Interest | C4 Therapeutics | 2018 | |
| Fritz Roth | Conflict of Interest | Ranomics, Inc. | 2017 | |
| Fritz Roth | Conflict of Interest | Ranomics, Inc. | 2017 | |
| Fritz Roth | Conflict of Interest | SeqWell, Inc. | 2017 | |
| William Kaelin | Conflict of Interest | Peloton Therapeutics, Inc. | 2017 | |
| Cigall Kadoch | Conflict of Interest | Foghorn Therapeutics, Inc. | 2017 | |
| Raul Mostoslavsky | Conflict of Interest | Galilei Biosciences Inc. | 2017 | |
| Nathanael Gray | Conflict of Interest | C4 Therapeutics | 2018 | |
| Cigall Kadoch | Conflict of Interest | Foghorn Therapeutics | 2018 | |
| Cigall Kadoch | Conflict of Interest | Foghorn Therapeutics | 2018 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.